Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched

This article was originally published in The Pink Sheet Daily

Executive Summary

After seven years of trying to get ceftobiprole approved in the U.S., Basilea said it would not run further clinical trials without a partner. Plans for a launch in Europe remain on track.

You may also be interested in...



Keeping Track: So. Much. News.

The latest drug development news and highlights from our US FDA Performance Tracker.

Basilea Plans European Ceftobiprole Launches In Second-Quarter 2014

The broad-spectrum cephalosporin, the first in a potential portfolio of hospital products for severe infections from the Swiss company, is nearing the market in the U.K. and Scandinavia.

Pfizer's Prevnar 20 Edges Closer To Infant Market, But Phase III Raises Some Questions

The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel